Gapping up
In reaction to strong earnings/guidance:
- IGT +11.4%, SE +4.9%, SY +1.5%, PLT +1.3%
Select oil/gas related names showing strength:
- TOT +7.5%, USO +6.7%, BP +5.6%, RDS.A +5.4%, SLB +4.9%, MPC +4.3%, HAL +4.3%, XLE +3.8%, XOM +3.4%, PSX +1.5%
Other news:
- FLGT +30.3% (receives emergency use authorization from the FDA for its RT-PCR test for detection of SARS-CoV-2, the virus that causes COVID-19)
- MRNA +27.9% (announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the Phase 1 study)
- VIR +11.9% (announces publication of Potential Therapeutic COVID-19 antibody published in Nature)
- CEMI +11.2% (signs multi-year, non-exclusive agreement with Thermo Fisher Scientific's healthcare channel, to distribute Chembio's DPP COVID-19 System in the United States)
- DCPH +4.5% (confirms FDA has approved QINLOCK for advanced gastrointestinal stromal tumor)
- TEVA +2.9% (China NMPA has approved AUSTEDO for the treatment of chorea) .
Analyst comments:
- MCFT +5.3% (upgraded to Buy from Neutral at B. Riley FBR)
- BBY +3.1% (upgraded to Outperform from Market Perform at Telsey Advisory Group )
- NVDA +2.9% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- SVMK +2.4% (upgraded to Overweight from Equal Weight at Wells Fargo)
- KHC +2.2% (upgraded to Buy from Neutral at BofA/Merrill)
- CPT +1.4% (upgraded to Buy from Neutral at BofA/Merrill)